On March 3, 2023, BD's 50th Anniversary Celebration of Flow Cytometry was grandly held in Shanghai. Experts from various fields such as scientific research, clinical practice, and industry gathered to discuss the application hotspots, challenges, and future trends of flow cytometry with great foresight. Since BD introduced the world's first large-scale commercial flow cytometer, FACS, in 1973, flow cytometry technology has evolved into an indispensable cornerstone research method across the entire chain from scientific research to clinical applications. It is widely used in numerous fields including immunology, molecular biology, bacteriology, virology, cancer biology, and infectious disease monitoring. In recent years, it has played a significant role in COVID-19 infection research.
At this ceremony, BD announced the launch of CellViewTMBD FACSDiscover with High-Speed Imaging TechnologyTMS8 Cell Sorter Officially Launched in China. This is the world's first full-spectrum flow cytometry cell sorter with image verification functionality, marking a...×The comprehensive launch of a new era of "spectrum" flow technology. In addition, BD exhibited the full range of flow innovation products such as BD FACSDuet™, BD FACSLyric™, and BD FACSymphony, committed to providing clinical and research workers with diversified choices and one-stop solutions.
BD FACSDiscoverTMS8 Cell Sorter Officially Launched in China
BD FACS 50 Years: Driving Rapid and In-Depth Development in Cell Research through Technological Innovation
Flow cytometry is a technology that studies multiple biological functions of individual cells or biological particles at the cellular level, featuring multi-parameter, high speed, high precision, and high accuracy. It combines quantitative, qualitative analysis, and targeted screening, making it one of the most advanced cell research technologies today.
For 50 years, BD Medical has taken innovation as its primary driving force and practical application scenarios in scientific research as the breakthrough point, continuously leading the leapfrog development of flow cytometry. From the world’s first fully automatic 4-color flow cytometer to the first 7-laser flow cytometer; from the watershed moment of pioneering sorting history with light-coupled quartz cuvette technology to building an interconnected flow cytometry lab that evolves with the times; from integrating compensation algorithms and spectral algorithms to launching the epoch-making CellView.TMTechnology, with each innovative breakthrough, not only helps researchers uncover the mysteries of cells but also continuously drives the creation of new clinical immunotherapy solutions.
The BD FACSDiscover launched this timeTMS8 Cell Sorter, equipped with the latest patented CellViewTMHigh-speed image technology has enabled precise screening based on real-time image results, bringing cell sorting into the "image×The "Spectrum" Era. This breakthrough allows researchers to obtain massive and precise information that cannot be acquired in traditional laboratories, thereby enabling the analysis and sorting of previously unidentifiable cells. It aids in exploring more complex biological questions, such as how cells produce, function, interact, and investigating the exact location of viruses or proteins within cells.
Lian Zhexiong, Vice President of Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, and "Changjiang Scholar," stated: "Since its inception, flow cytometry has consistently served as 'the innovation behind the innovation,' acting as the driving force behind numerous major scientific discoveries. From the early identification of leukemia stem cells and the discovery of the T-cell receptor to recent advancements such as immunocyte therapy, COVID-19 vaccine and antibody development, flow cytometry has played a pivotal role. The CellView introduced by BD Medical this time...TM"The technology is extremely groundbreaking, and I look forward to trying it out as soon as possible to help our scientists launch new projects, answer previously unimaginable questions, and contribute to achieving more significant scientific research outcomes."
From Research to Clinical Application, Diversified Products Build a Full-Chain Flow Cytometry Solution
With the maturation and popularization of flow cytometry technology, BD is providing comprehensive and standardized solutions for every link in the industry chain, based on the practical application scenarios and needs of production, academia, research, and healthcare.
In the industry, flow cytometry technology spans several critical stages, including drug discovery, in vitro diagnostics, stem cell research, and in vitro toxicity testing. It is highly anticipated in many current hot fields, such as the development of CAR-T and TCR-T therapies in the biopharmaceutical sector. At the same time, this technology is widely used in various clinical departments, such as laboratory medicine, oncology, infectious diseases, neurology, hematology, rheumatology and immunology, pediatrics, and allergy departments. It plays a significant role in numerous severe and acute conditions, including AIDS, coronavirus infection, lymphoma, acute leukemia, and organ transplantation. For instance, during the global outbreak of coronavirus infection, flow cytometry provided indispensable technical support in therapy development, testing, and post-recovery immune monitoring.
Wang Hui, Deputy Dean of Beijing Ludaopei Hematology Research Institute and Deputy Director of the Laboratory Department (Vice-Dean level) of Ludaopei Medical Group, stated: "Flow cytometry technology has been widely used throughout the entire life health chain, from basic research, drug development, disease diagnosis, efficacy monitoring, to prognosis evaluation, becoming an important cornerstone technology supporting the development of precision medicine and translational medicine in China. At present, there is still room for further improvement in the popularity, standardization, application depth, and talent cultivation of flow cytometry technology in China. We look forward to deep collaboration to better and more quickly unleash the potential of this technology, bringing value changes to clinical practice and patients."
Wang Tong, Vice President of BD's Greater China Biosciences Division, stated: "As the pioneer and innovator of large-scale commercial flow cytometry, BD has journeyed for 50 years. At this significant milestone, we are greatly honored to once again lead the industry into the 'Graph × Spectrum' new era with disruptive innovation. We believe this breakthrough technology will accelerate and transform the way scientists study cells, bringing a qualitative leap to research fields such as immunology, cell biology, and genomics."
Deng Jianmin, Global Senior Vice President of BD and General Manager of Greater China, stated: "Biosciences is an important component of BD's business in China. From the introduction of the first flow cytometer in China in 1983 to today’s 'Spectrum' flow equipment representing the latest global technology, BD has been continuously introducing the most cutting-edge innovations in this field to China, playing a significant role across the entire industrial chain including research, clinical applications, and localized GMP production. We are deeply proud of this. We also look forward to closer collaboration with Chinese researchers and clinicians as technology and solutions continue to evolve, bringing more meaningful changes and assistance to China’s scientific research and patient communities."